Your browser doesn't support javascript.
loading
CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy?
Zhang, Chunxue; Fei, Yuxiang; Wang, Hui; Hu, Sheng; Liu, Chao; Hu, Rong; Du, Qianming.
Afiliación
  • Zhang C; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Fei Y; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Wang H; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Hu S; College of Pharmacy, Xinjiang Medical University, Urumqi, China.
  • Liu C; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Hu R; State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu Nanjing, China.
  • Du Q; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Front Pharmacol ; 14: 1113378, 2023.
Article en En | MEDLINE | ID: mdl-37007004
Cancer immunotherapy has opened a new landscape in cancer treatment, however, the poor specificity and resistance of most targeted therapeutics have limited their therapeutic efficacy. In recent years, the role of CAFs in immune regulation has been increasingly noted as more evidence has been uncovered regarding the link between cancer-associated fibroblasts (CAFs) and the evolutionary process of tumor progression. CAFs interact with immune cells to shape the tumor immune microenvironment (TIME) that favors malignant tumor progression, a crosstalk process that leads to the failure of cancer immunotherapies. In this review, we outline recent advances in the immunosuppressive function of CAFs, highlight the mechanisms of CAFs-immune cell interactions, and discuss current CAF-targeted therapeutic strategies for future study.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza